Literature DB >> 30506168

Minimally Invasive Treatment for Benign Prostatic Hyperplasia: Economic Evaluation from a Standardized Hospital Case Costing System.

Andrew D Brown1, Steffan F Stella2, Martin E Simons3.   

Abstract

PURPOSE: Minimally invasive alternatives to transurethral resection of the prostate (TURP) such as prostate arterial embolization (PAE) and photoselective vaporization of the prostate (PVP) are being explored as adjuncts in the care of patients with benign prostatic hyperplasia. However, there are conflicting reports of the costs of these procedures. The purpose of this study was to compare the direct and indirect hospital costs of TURP, PAE and PVP.
MATERIALS AND METHODS: A chart review was performed in patients who underwent TURP, PVP and PAE from April 2015 to March 2017. All hospital costs were collected in accordance with the Ontario Case Costing Initiative, a standardized medical case costing system. Costs were characterized as direct or indirect and fixed or variable. Probabilistic sensitivity analysis was conducted to study cost uncertainty.
RESULTS: During the study period, a total of 209 men underwent TURP, 28 PVP and 21 PAE. Mean age (years) was as follows: TURP 71.43; PVP 73.66; PAE 70.77 (p = 0.366). Mean length of stay (days) was as follows: TURP 1.63; PVP 1.55; PAE 1 (p = 0.076). Total costs of the PAE group ($3829, SD $1582) were less than both PVP ($5719, SD $1515) and TURP groups ($5034, SD $1997, p < 0.001). There was no significant difference in direct costs between the groups. Monte Carlo simulation demonstrated that PAE was the least costly alternative majority of the time.
CONCLUSIONS: The total hospital costs of PAE at our institution are significantly lower than those of PVP and TURP.

Entities:  

Keywords:  BPH; Cost; Photoselective vaporization of the prostate (PVP); Prostate artery embolization (PAE); TURP

Mesh:

Year:  2018        PMID: 30506168     DOI: 10.1007/s00270-018-2132-8

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

Review 1.  Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Karen Ann McCutcheon; Michael Borofsky; Shamar Young; Jafar Golzarian; Myung Ha Kim; Vikram M Narayan; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2022-03-29

Review 2.  Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis.

Authors:  Juan Va Franco; Jae Hung Jung; Mari Imamura; Michael Borofsky; Muhammad Imran Omar; Camila Micaela Escobar Liquitay; Shamar Young; Jafar Golzarian; Areti Angeliki Veroniki; Luis Garegnani; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2021-07-15

3.  Prostatic Artery Embolization for Benign Prostatic Hyperplasia: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-06-04

4.  Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Karen Ann McCutcheon; Michael Borofsky; Shamar Young; Jafar Golzarian; Balaji Reddy; Tae Young Shin; Myung Ha Kim; Vikram Narayan; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2020-12-19

5.  Advanced image guidance for prostatic artery embolization - a multicenter technical note.

Authors:  Francisco Cesar Carnevale; Timothy McClure; Farah Cadour; Vincent Vidal; André Moreira de Assis; Airton Mota Moreira; Arthur Diego Dias Rocha; Aya Rebet; Charles Nutting
Journal:  CVIR Endovasc       Date:  2021-08-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.